90 related articles for article (PubMed ID: 30654205)
1. Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients.
Kurmi M; Sahu A; Ladumor MK; Kumar Bansal A; Singh S
J Pharm Biomed Anal; 2019 Mar; 166():174-182. PubMed ID: 30654205
[TBL] [Abstract][Full Text] [Related]
2. Stability behaviour of antiretroviral drugs and their combinations. 8: Characterization and in-silico toxicity prediction of degradation products of efavirenz.
Kurmi M; Sahu A; Singh DK; Singh IP; Singh S
J Pharm Biomed Anal; 2018 Jan; 148():170-181. PubMed ID: 29055875
[TBL] [Abstract][Full Text] [Related]
3. Stability behaviour of antiretroviral drugs and their combinations. 2: Characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry.
Kurmi M; Kushwah BS; Sahu A; Narayanam M; Singh S
J Pharm Biomed Anal; 2016 Jun; 125():245-59. PubMed ID: 27042808
[TBL] [Abstract][Full Text] [Related]
4. Stability behaviour of antiretroviral drugs and their combinations. 3: Characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry.
Kurmi M; Singh DK; Tiwari S; Sharma P; Singh S
J Pharm Biomed Anal; 2016 Sep; 128():438-446. PubMed ID: 27344633
[TBL] [Abstract][Full Text] [Related]
5. Stability behaviour of antiretroviral drugs and their combinations. 10: LC-HRMS, LC-MS
Singh DK; Sahu A; Wani AA; Bharatam PV; Kotimoole CN; Batkulwar KB; Deshpande AY; Giri S; Singh S
Eur J Pharm Biopharm; 2019 Sep; 142():165-178. PubMed ID: 31226366
[TBL] [Abstract][Full Text] [Related]
6. Stability behaviour of antiretroviral drugs and their combinations. 5: Characterization of novel degradation products of abacavir sulfate by mass and nuclear magnetic resonance spectrometry.
Kurmi M; Sahu A; Singh S
J Pharm Biomed Anal; 2017 Feb; 134():372-384. PubMed ID: 27889293
[TBL] [Abstract][Full Text] [Related]
7. Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties.
Kurmi M; Sahu A; Balhara A; Singh IP; Kulkarni S; Singh NK; Garg P; Singh S
J Pharm Biomed Anal; 2020 Jan; 178():112911. PubMed ID: 31627078
[TBL] [Abstract][Full Text] [Related]
8. Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate.
Golla VM; Kurmi M; Shaik K; Singh S
J Pharm Biomed Anal; 2016 Nov; 131():146-155. PubMed ID: 27589032
[TBL] [Abstract][Full Text] [Related]
9. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
11. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Moyle GJ; Orkin C; Fisher M; Dhar J; Anderson J; Wilkins E; Ewan J; Ebrahimi R; Wang H;
PLoS One; 2015; 10(2):e0116297. PubMed ID: 25658097
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
[TBL] [Abstract][Full Text] [Related]
16. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
[TBL] [Abstract][Full Text] [Related]
17. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
[TBL] [Abstract][Full Text] [Related]
18. Degradants of Tenofovir Disoproxil Fumarate Under Forced Yet Mild Thermal Stress: Isolation, Comprehensive Structural Elucidation, and Mechanism.
Ranga M; Modini AK; Nallajarla AK; Doddipalla R; Kaliyaperumal M; Goswami A
AAPS PharmSciTech; 2023 Jun; 24(6):139. PubMed ID: 37349667
[TBL] [Abstract][Full Text] [Related]
19. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.
Tebas P; Kumar P; Hicks C; Granier C; Wynne B; Min S; Pappa K
AIDS; 2015 Nov; 29(18):2459-64. PubMed ID: 26355674
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
